Chronic obstructive pulmonary disease exacerbation resident survival guide: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 22: | Line 22: | ||
* Air pollutants | * Air pollutants | ||
== | ==Treatment Setting and Severity== | ||
{{Family tree/start}} | {{Family tree/start}} | ||
{{Family tree |border=2|boxstyle=background: WhiteSmoke;|A1|A1=<div style="float: center; text-align: left; height: | {{Family tree |border=2|boxstyle=background: WhiteSmoke;|A1|A1=<div style="float: center; text-align: left; height: 5.5em; width: 12em; padding: 1em">'''COPD Exacerbation''' <BR> ❑ Cough ↑ <BR> ❑ Dyspnea ↑ <BR> ❑ Sputum ↑ </div>}} | ||
{{Family tree |!| | | | | | | | | |}} | {{Family tree |!| | | | | | | | | |}} | ||
{{Family tree |border=2|boxstyle=background:WhiteSmoke;|)|-|B1|B1=<div style="float: left; text-align: left; height: | {{Family tree |border=2|boxstyle=background:WhiteSmoke;|)|-|B1|B1=<div style="float: left; text-align: left; height: 5em; width: 41em; padding: 1em"> | ||
'''1. Oxygen Supplement''' <BR> ❑ Pulse oximetry (maintain Sa<sub>O<sub>2</sub></sub> ≥88—92%)<ref name="Austin-2010">{{Cite journal | last1 = Austin | first1 = MA. | last2 = Wills | first2 = KE. | last3 = Blizzard | first3 = L. | last4 = Walters | first4 = EH. | last5 = Wood-Baker | first5 = R. | title = Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. | journal = BMJ | volume = 341 | issue = | pages = c5462 | month = | year = 2010 | doi = | PMID = 20959284 }}</ref> <BR> ❑ Arterial blood gas (if acute or acute-on-chronic respiratory failure is suspected)<sup>†</sup></div>}} | |||
{{Family tree |!| | | | | | | | | |}} | |||
{{Family tree |border=2|boxstyle=background:WhiteSmoke;|)|-|C1|C1=<div style="float: left; text-align: left; height: 7em; width: 41em; padding: 1em"> | |||
'''2. Indications for ICU Admission'''<BR>❑ Hemodynamic instability <BR> ❑ Changes in mental status (confusion, lethargy, coma) <BR> ❑ Severe dyspnea that responds inadequately to initial emergency therapy <BR> ❑ Worsening hypoxemia (Pa<sub>O<sub>2</sub></sub> <40 mm Hg) and/or respiratory acidosis (pH <7.25)</div>}} | |||
-- | {{Family tree |!| | | | | | | | | |}} | ||
{{Family tree |border=2|boxstyle=background:WhiteSmoke;|)|-|D1|D1=<div style="float: left; text-align: left; height: 23em; width: 41em; padding: 1em"> | |||
'''Indications for | '''3. Indications for Hospitalization''' <BR> ❑ Marked increase in intensity of symptoms (eg, sudden development of resting dyspnea) <BR> ❑ Severe underlying COPD (GOLD 3—4 categories) <BR> ❑ Onset of new physical signs (eg, cyanosis, peripheral edema) <BR> ❑ Failure of an exacerbation to respond to initial medical management <BR> ❑ Presence of serious comorbidities (eg, heart failure or newly occurring arrhythmias) <BR> ❑ Frequent exacerbations (≥2 events per year) <BR> ❑ Older age (>65 years) <BR> ❑ Insufficient home support | ||
---- | ---- | ||
''' | '''4. Assessment of Severity of Exacerbation''' <BR> ❑ Chest radiograph (exclude alternative diagnoses) <BR> ❑ ECG (identify coexisting cardiac problems) <BR> ❑ Whole-blood count (identify polycythemia, anemia, or leukocytosis) <BR> ❑ Electrolytes and glucose (identify electrolyte disturbances or hyperglycemia) <BR> ❑ Sputum purulence (if ⊕ → give empiric antibiotics)</div>}} | ||
{{Family tree |!| | | | | | | | | |}} | {{Family tree |!| | | | | | | | | |}} | ||
Line 69: | Line 58: | ||
==Management== | |||
{{Family tree/start}} | {{Family tree/start}} |
Revision as of 18:58, 14 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Definition
- Exacerbation of COPD is an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond normal day-to-day variations and leads to a change in medication.[1][2][3]
- The diagnosis of an exacerbation relies exclusively on the clinical presentation of the patient complaining of an acute change of symptoms (baseline dyspnea, cough, and/or sputum production) that is beyond normal day-to-day variation.[4]
Causes
Life-Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
- Respiratory tract infections (~½)
- Unknown (~⅓)
- Air pollutants
Treatment Setting and Severity
COPD Exacerbation ❑ Cough ↑ ❑ Dyspnea ↑ ❑ Sputum ↑ | |||||||||||||||||||||
1. Oxygen Supplement ❑ Pulse oximetry (maintain SaO2 ≥88—92%)[5] ❑ Arterial blood gas (if acute or acute-on-chronic respiratory failure is suspected)† | |||||||||||||||||||||
2. Indications for ICU Admission ❑ Hemodynamic instability ❑ Changes in mental status (confusion, lethargy, coma) ❑ Severe dyspnea that responds inadequately to initial emergency therapy ❑ Worsening hypoxemia (PaO2 <40 mm Hg) and/or respiratory acidosis (pH <7.25) | |||||||||||||||||||||
3. Indications for Hospitalization 4. Assessment of Severity of Exacerbation ❑ Chest radiograph (exclude alternative diagnoses) ❑ ECG (identify coexisting cardiac problems) ❑ Whole-blood count (identify polycythemia, anemia, or leukocytosis) ❑ Electrolytes and glucose (identify electrolyte disturbances or hyperglycemia) ❑ Sputum purulence (if ⊕ → give empiric antibiotics) | |||||||||||||||||||||
123 | |||||||||||||||||||||
†PaO2 <60 mm Hg with or without PaCO2 >50 mm Hg in ambient air
Management
COPD Exacerbation ↑cough, ↑dyspnea, ↑sputum, ↑wheezing, fever or chest tightness | |||||||||||||||||||||||||||
Admission | |||||||||||||||||||||||||||
Assessment : 1-O2 sat+ ABG 2-CXR 3-EKG 4-CBC
1-Inhaled bronchodilators 2-Systemic corticosteroids 3-Empirical antibiotics 4-O2 (target Sat >90%) | Corticosteroids(Solumedrol) Methylprednisolone 125 mg×1 dose followed with 60-80 mg Q8-12based on severity IV Solumedrol to PO Prednisone taper 4--60 mg Q 8-12 2-5 days taper depending on severity Antibiotics Group A* Doxycycline Cap Vibramycin PO 100 mg Q12H (if unable to tolerate choose Cefpodoxime Tab Vantin PO 200 mg Q12H) Group B* Ceftriaxone Inj Rocephin 1GM D5W50 ml Q24H 200 ml/Hr (If Beta-Lactam allergy choose Levofloxacin Tab Levaquin PO 500 mg daily ) Group C* Ciprofloxacin Tab CiproPO 250 Daily or Ciprofloxacin Inj Cipro 400 mg premixed at 400 mg /200 ml Q12H 200 ml/Hr. | ||||||||||||||||||||||||||
Respiratory acidosis? OR PH≤35? OR PaCo2≥45? OR Severe signs of dyspnea? OR Accessory muscles use, paradoxical motion of abdomen, retraction of intercostal space | |||||||||||||||||||||||||||
No | Yes | ||||||||||||||||||||||||||
Continue the same management | ICU Admission | ||||||||||||||||||||||||||
Non-invasive ventilation | |||||||||||||||||||||||||||
Unable to tolerate NIV? Severe hemodynamic instability? Resp/cardiac arrest ? | |||||||||||||||||||||||||||
Invasive mechanical ventilation | |||||||||||||||||||||||||||
Do's
- Monitor fluid balance,nutrition and patient condition closely.
- Consider subcutaneous heparin or low molecular weight heparin.
- Treat associated conditions if exist(e.g., heart failure,arrhythmias).
Don'ts
- Spirometry is not recommended during an exacerbation because it can be difficult to perform and measurements are not accurate enough.
References
- ↑ Burge, S.; Wedzicha, JA. (2003). "COPD exacerbations: definitions and classifications". Eur Respir J Suppl. 41: 46s–53s. PMID 12795331. Unknown parameter
|month=
ignored (help) - ↑ Celli, BR.; Barnes, PJ. (2007). "Exacerbations of chronic obstructive pulmonary disease". Eur Respir J. 29 (6): 1224–38. doi:10.1183/09031936.00109906. PMID 17540785. Unknown parameter
|month=
ignored (help) - ↑ Rodriguez-Roisin, R. (2000). "Toward a consensus definition for COPD exacerbations". Chest. 117 (5 Suppl 2): 398S–401S. PMID 10843984. Unknown parameter
|month=
ignored (help) - ↑ Vestbo, J.; Hurd, SS.; Agustí, AG.; Jones, PW.; Vogelmeier, C.; Anzueto, A.; Barnes, PJ.; Fabbri, LM.; Martinez, FJ. (2013). "Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary". Am J Respir Crit Care Med. 187 (4): 347–65. doi:10.1164/rccm.201204-0596PP. PMID 22878278. Unknown parameter
|month=
ignored (help) - ↑ Austin, MA.; Wills, KE.; Blizzard, L.; Walters, EH.; Wood-Baker, R. (2010). "Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial". BMJ. 341: c5462. PMID 20959284.